2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Boston Scientific, we had the pleasure of speaking with Aparna Kalyan, MD, an associate professor of medicine (Hematology and Oncology), and Samdeep K. Mouli, MD, MS, an assistant professor of radiology (Vascular and Interventional Radiology), both at the Feinberg School of Medicine of Northwestern Medicine, to discuss a paper they co-authored that compared real-world personalized multidisciplinary tumor board recommendations with the Barcelona Clinic Liver Cancer (BCLC) algorithm and the advantages of incorporating center expertise, patient-specific characteristics, and the known multi-directional treatment recommendation process into patient care in hepatocellular carcinoma (HCC).
In the study, treatment-naïve patients with HCC who had been discussed at a multidisciplinary tumor board (MDT) between 2010 and 2013 were included to allow for a minimum follow-up of 5 years. The MDT-recommended first treatment, including resection, transplant, ablation, transarterial radioembolization (Y90), transarterial chemoembolization, sorafenib, or palliation, as well as subsequent therapy was recorded. Overall survival (OS) analyses were done in the intention-to-treat (ITT) population and stratified by Barcelona Clinic Liver Cancer (BCLC) stage.
The results showed that 321 patients were treated in the 4-year period. The median age was 62 years, and the majority of patients were male (73%), had hepatitis C (41%), and Y90 as initial treatment (52%). There was a 76% rate of BCLC-discordant first treatment. Moreover, the median OS was not reached, 51.0 months, 25.4 months, and 13.4 months for BCLC stages A, B, C and D, respectively.
This approach demonstrated an expected OS in patients with BCLC stage A disease, and surpassed general guideline expectations for those with BCLC stage B, C, and D disease.
In our exclusive interview, Kalyan and Mouli discuss the importance of multidisciplinary care in HCC, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.
Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.